I recently read the EMA (European Medicines Agency) report on Genentech’s (Roche) attempt to file Perjeta (Pertuzumab) as a Quality–by–Design (QbD) submission. I was excited to see a Biologics product (monoclonal antibody) going through QbD for the first time. I tout their effort. Sadly, FDA rejected it as a...